AbbVie’s Promising Phase 3 Study on Atogepant for Menstrual Migraine Prevention

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is currently conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine. The study aims to assess the efficacy, safety, and tolerability of Atogepant, an investigational drug, in preventing menstrual migraines in adult women. This study is significant as it targets a specific type of migraine that affects many women, potentially offering a new preventive treatment option.

The intervention being tested is Atogepant, an oral tablet designed to prevent menstrual migraines. Participants are randomly assigned to receive either Atogepant or a placebo during the double-blind period, followed by Atogepant during the open-label period.

The study is interventional with a randomized allocation and a parallel intervention model. It employs triple masking, meaning the participant, investigator, and outcomes assessor are unaware of the treatment assignments. The primary purpose of the study is treatment-focused.

The study began on February 10, 2025, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

The market implications of this study could be significant for AbbVie, potentially boosting its stock performance and investor confidence if Atogepant proves effective. This development could also impact competitors in the migraine treatment market, as a successful outcome may shift market dynamics.

The study is ongoing, and further details are available on the ClinicalTrials portal.